PVP Ventures Share Price Today

Evervie Health pays ₹13.46 crore NCD interest ahead of schedule

Evervie Health Limited paid ₹13.46 crore interest on NCDs on October 8, 2026. Payment covers interest due for December 31, 2026, and March 31, 2027. Series A debentures accounted for ₹8.53 crore of the total advance payment. No change in quarterly interest payment frequency or contractual terms.

PVP Ventures submits updated FY26 annual report with addendum and corrigendum

PVP Ventures Limited filed an updated FY2025-26 Annual Report on October 6, 2026, incorporating an addendum (August 20) and a corrigendum (August 29) to the original report submitted August 14, 2026. The addendum includes a Regulation 45(3) compliance certificate certifying that 77% of company assets (₹179.40 crore) are invested in the new healthcare activity, satisfying the 50% threshold for the proposed name change to Evervie Health Limited. The corrigendum revises AGM Item No. 10 to include the re-appointment of Prasad V. Potluri as Chairman and Managing Director for five years from the conclusion of the 35th AGM. On a standalone basis, the company turned profitable in FY2025-26 with a profit after tax of ₹72.32 lakhs versus a loss of ₹390.40 lakhs in FY2024-25; standalone revenue from operations rose to ₹3,292.29 lakhs from ₹1,690.24 lakhs. The company completed acquisitions of majority stakes in Biohygea Global Private Limited, Optimus Oncology Private Limited, and 7Med India Private Limited during the year, and issued NCDs aggregating ₹150 crores.

PVP Ventures pays ₹1.04 crore NCD interest after three-day delay

PVP Ventures Ltd paid ₹1.04 crore interest on two NCD series on October 3, 2026. Payment was delayed by three days from the September 30, 2026 due date. Company cited a technical issue as the reason for the non-payment on time. Total issue size of the two debenture series is ₹150 crore.

PVP Ventures accepts CEO and COO resignations effective September 24

PVP Ventures accepted resignations of CEO Ellen Jane Feehan and COO Neeraja Nagarajan effective September 24, 2026. Feehan cited unavoidable personal health reasons for not joining the company. Nagarajan resigned due to non-alignment with the incoming CEO and leadership style differences. Both executives held roles as Executive Directors in addition to their operational titles. Disclosures made under Regulation 30 of SEBI (LODR) Regulations, 2015.

PVP Ventures closes trading window ahead of Q2FY27 results

PVP Ventures Ltd closed its trading window effective October 1, 2026. The window remains closed until 48 hours after Q2FY27 results declaration. Closure applies to designated persons, relatives, and insiders per SEBI regulations. Board meeting date for reviewing standalone and consolidated results to be announced later.

PVP Ventures accepts resignation of Executive Director and COO

Dr. Neeraja Nagarajan resigned as Executive Director and COO of PVP Ventures Limited. Cessation date is September 24, 2026, citing personal reasons. Announcement filed under SEBI (LODR) Regulations 2015, Regulation 30(6). Further disclosures regarding the change will be made in due course.